These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22736548)

  • 1. Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins.
    Rosenberg AS; Verthelyi D; Cherney BW
    J Pharm Sci; 2012 Oct; 101(10):3560-7. PubMed ID: 22736548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective.
    Bee JS; Goletz TJ; Ragheb JA
    J Pharm Sci; 2012 Oct; 101(10):3580-5. PubMed ID: 22736570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations.
    Johnson R; Jiskoot W
    J Pharm Sci; 2012 Oct; 101(10):3586-92. PubMed ID: 22736238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein particles: what we know and what we do not know.
    Ripple DC; Dimitrova MN
    J Pharm Sci; 2012 Oct; 101(10):3568-79. PubMed ID: 22736521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products.
    Marszal E; Fowler E
    J Pharm Sci; 2012 Oct; 101(10):3555-9. PubMed ID: 22736535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation.
    Carpenter J; Cherney B; Lubinecki A; Ma S; Marszal E; Mire-Sluis A; Nikolai T; Novak J; Ragheb J; Simak J
    Biologicals; 2010 Sep; 38(5):602-11. PubMed ID: 20702108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development.
    Lu Y; Khawli LA; Purushothama S; Theil FP; Partridge MA
    J Immunol Res; 2016; 2016():8141269. PubMed ID: 27642612
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety issues specific to clinical development of protein therapeutics.
    Haller CA; Cosenza ME; Sullivan JT
    Clin Pharmacol Ther; 2008 Nov; 84(5):624-7. PubMed ID: 18701885
    [No Abstract]   [Full Text] [Related]  

  • 9. Strategies for the preclinical and clinical characterization of immunogenicity.
    Koren E; Mytych D; Koscec M; Ferbas J; Gupta S; Moxness M; Swanson S
    Dev Biol (Basel); 2005; 122():195-200. PubMed ID: 16375262
    [No Abstract]   [Full Text] [Related]  

  • 10. Journal of Pharmaceutical Sciences. Editorial.
    Carpenter JF
    J Pharm Sci; 2012 Oct; 101(10):3554. PubMed ID: 22736509
    [No Abstract]   [Full Text] [Related]  

  • 11. Taking immunogenicity assessment of therapeutic proteins to the next level.
    Büttel IC; Chamberlain P; Chowers Y; Ehmann F; Greinacher A; Jefferis R; Kramer D; Kropshofer H; Lloyd P; Lubiniecki A; Krause R; Mire-Sluis A; Platts-Mills T; Ragheb JA; Reipert BM; Schellekens H; Seitz R; Stas P; Subramanyam M; Thorpe R; Trouvin JH; Weise M; Windisch J; Schneider CK
    Biologicals; 2011 Mar; 39(2):100-9. PubMed ID: 21353596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follow-on protein products: scientific issues, developments and challenges.
    Rathore AS
    Trends Biotechnol; 2009 Dec; 27(12):698-705. PubMed ID: 19846228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations.
    Jahn EM; Schneider CK
    N Biotechnol; 2009 Jun; 25(5):280-6. PubMed ID: 19491045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins.
    Sauna ZE; Lagassé D; Pedras-Vasconcelos J; Golding B; Rosenberg AS
    Trends Biotechnol; 2018 Oct; 36(10):1068-1084. PubMed ID: 29908714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of immunogenic response to protein therapeutics.
    Singh SK; Cousens LP; Alvarez D; Mahajan PB
    Biologicals; 2012 Sep; 40(5):364-8. PubMed ID: 22770604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.
    Smith A; Manoli H; Jaw S; Frutoz K; Epstein AL; Khawli LA; Theil FP
    J Immunol Res; 2016; 2016():2342187. PubMed ID: 27579329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The Identification of Critical Quality Attributes (CQAs) for the Development of Antibody Drugs].
    Saitoh S
    Yakugaku Zasshi; 2018; 138(12):1475-1481. PubMed ID: 30504661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.
    Singh SK; Afonina N; Awwad M; Bechtold-Peters K; Blue JT; Chou D; Cromwell M; Krause HJ; Mahler HC; Meyer BK; Narhi L; Nesta DP; Spitznagel T
    J Pharm Sci; 2010 Aug; 99(8):3302-21. PubMed ID: 20310025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and its impact on benefit/risk considerations in the authorisation of biopharmaceuticals.
    Büttel I; Völler K; Schneider C;
    Curr Drug Saf; 2010 Oct; 5(4):287-92. PubMed ID: 20615175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.
    Chirmule N; Jawa V; Meibohm B
    AAPS J; 2012 Jun; 14(2):296-302. PubMed ID: 22407289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.